Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40

SGN-40 is a humanized IgG1 antihuman CD40 that is currently in a phase I clinical trial for the treatment of multiple myeloma. As surface CD40 expression on B-lineage cells is maintained from pro-B cells to plasma cells, SGN-40 may be applicable to treatment of other B-cell neoplasias, including non...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2005-09, Vol.65 (18), p.8331-8338
Hauptverfasser:	LAW, Che-Leung, GORDON, Kristine A, WANT, Alan F, GREWAL, Iqbal S, COLLIER, John, KLUSSMAN, Kerry, MCEARCHERN, Julie A, CERVENY, Charles G, MIXAN, Bruce J, LEE, Wyne P, ZHONGHAU LIN, VALDEZ, Patricia
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antibody-Dependent Cell Cytotoxicity Antineoplastic agents Apoptosis - drug effects Apoptosis - immunology B-Lymphocytes - cytology B-Lymphocytes - drug effects B-Lymphocytes - immunology Biological and medical sciences Caspase 3 Caspases - metabolism CD40 Antigens - immunology Cell Growth Processes - drug effects Cell Growth Processes - immunology Cell Line, Tumor Enzyme Activation Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulin G - immunology Immunoglobulin G - pharmacology Immunoglobulinopathies Immunopathology Immunotherapy Lymphoma, B-Cell - immunology Lymphoma, B-Cell - pathology Lymphoma, B-Cell - therapy Medical sciences Mice Mice, SCID Pharmacology. Drug treatments Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!